What Resyca does

Resyca is a Netherlands-based medical device company founded in 2020 as a joint venture between Medspray and Bespak (formerly part of Recipharm, now standalone and backed by EQT Private Equity). The company develops syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations, using proprietary silicon micro-pore nozzle chip technology manufactured via semiconductor processes. The platform exploits the Rayleigh breakup principle to generate gentle, propellant-free aerosol droplets that preserve the molecular integrity of fragile biologics, mRNA, and other complex formulations, addressing a key limitation of propellant-based metered dose inhalers and dry powder inhalers that are designed for microgram-level potent drugs. Its product portfolio comprises four devices: PFSI (pre-filled syringe inhaler delivering over 60% lung deposition), Pulmospray (single-use disposable nebuliser for clinical settings), Ultra Soft Nasal Pump Spray (multi-dose nasal delivery for nose-to-brain targeting), and Soft Nasal Spray Adaptor (single-use CE-marked nasal device with up to 50% nasal cavity coverage).

Resyca operates exclusively as a B2B company serving pharmaceutical and biotech partners developing novel drug-device combination products. Its revenue model combines upfront and milestone-based licensing fees, ongoing royalties on partner net sales, device supply contracts (clinical and commercial), and end-to-end development services spanning feasibility, formulation optimization, device selection, regulatory submissions, and fill-finish. Named customers include Cyrano Therapeutics (exclusive license for smell loss treatment), Silo Pharma (intranasal PTSD drug), Thaerapy BV (pulmonary arterial hypertension), and strategic collaborators Stevanato Group and Aero Pump. Manufacturing is handled through parent Bespak (King's Lynn, UK) and Medspray (Enschede, Netherlands), with commercial operations anchored in Munich, Germany.

The company holds ISO 13485 certification (since 2022), EU MDR certification (since January 2025), and FDA QSR compliance, enabling support for combination product submissions in both EU and US markets. Resyca's strategic positioning targets high-growth therapeutic areas where existing inhaler technologies are inadequate, including biologics, mRNA therapeutics, nasal vaccines, and nose-to-brain CNS delivery, positioning the company as a platform enabling partner pipelines rather than a drug developer itself.

Name

Resyca

Legal name

Resyca B.V.

Website

https://resyca.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Resyca is a Netherlands-based medical device company developing syringe-based soft mist inhalers and nasal sprays for liquid pharmaceutical formulations. It serves pharmaceutical and biotech partners through licensing, device supply, and development services, using proprietary silicon micro-pore nozzle technology.

Ownership category

akta.pro rank

Product category

Inhalation Drug Delivery Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industries

Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

Keywords

• Soft mist inhalers
• Nasal drug delivery
• Drug-device combination products
• Pre-filled syringe inhalers
• Inhalation drug delivery

Headquarters

HQ city

Enschede

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Device Licensing and Royalties: Licensing of proprietary soft mist technology to pharmaceutical partners. Partners receive exclusive or non-exclusive rights to use Resyca's technology for specific drug products. Revenue includes upfront milestones and ongoing royalties based on net sales of marketed products.
2. Device Supply and Manufacturing: Supply of soft mist inhaler devices and components to pharmaceutical partners. Includes both clinical trial supply and commercial-scale supply. Manufacturing supported by Bespak and Medspray.
3. Development Services: Comprehensive services spanning early-stage feasibility, formulation optimisation, device selection, regulatory submissions, clinical trial supply, and fill-finish services. Full end-to-end partnership from concept to market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Resyca develops and manufactures syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations. The company's four product platforms — PFSI, Pulmospray, Ultra Soft Nasal Pump Spray, and Soft Nasal Spray Adaptor — leverage proprietary Rayleigh spray nozzle technology built on silicon micro-pore chips. Resyca sells these drug-device combination platforms to pharmaceutical and biotech partners through licensing, device supply contracts, and end-to-end development services from feasibility through commercial launch.

Product overview

Resyca offers a portfolio of four distinct soft mist drug delivery platforms: PFSI (Pre-Filled Syringe Inhaler) and Pulmospray for pulmonary inhalation delivery, and Ultra Soft Nasal Pump Spray and Soft Nasal Spray Adaptor for nasal delivery applications. All platforms utilise proprietary Medspray micro-nozzle technology based on silicon micro-pore chips that generate gentle, propellant-free soft mist aerosols via Rayleigh breakup theory. The PFSI and Soft Nasal Spray Adaptor support pre-filled syringe formats for clinical and commercial use, while Pulmospray offers on-site fillable single-use delivery. The Ultra Soft Nasal Pump Spray provides multidose nasal delivery with precise olfactory targeting for nose-to-brain therapies. These platforms are designed for liquid formulations of both biologics and small molecules, offering end-to-end services from early-stage development through commercial launch.

Differentiator

Problem solved

Functional benefit

Brands

• PFSI: Pre-Filled Syringe Soft Mist Inhaler - A ready-to-use, patient-friendly platform combining high-performance drug delivery with everyday convenience.
• Pulmospray
• Ultra Soft Nasal Pump Spray
• Soft Nasal Spray Adaptor

Products and services

• PFSI (Pre-Filled Syringe Inhaler) A ready-to-use, patient-friendly soft mist inhaler that combines high-performance drug delivery with everyday convenience. Built on a 1mL pre-filled glass syringe (Stevanato Alba), it delivers over 60% of the dose deep into the lungs using proprietary Rayleigh spray nozzle technology. Compact, pocket-sized, available in reusable and disposable configurations, designed for pharmaceutical partners developing pulmonary drug-device combination products.
• Pulmospray A single-use, disposable soft mist nebuliser with a 1mL plastic syringe fillable on-site with desired medication. CE-marked, propellant-free device using proprietary Rayleigh spray nozzle technology for gentle, efficient aerosolisation. Designed for hospitals, clinical studies, and acute treatments where 53–61% lung dose and single-use sterile systems are required.
• Ultra Soft Nasal Pump Spray A multi-dose precision nasal drug delivery device co-developed with Aero Pump, delivering a fine, low-velocity mist with 18× slower spray velocity using proprietary Rayleigh spray nozzle technology. Available in 45µL and 70µL pump volumes with 5–30mL fill capacities, designed for accurate deposition in posterior and olfactory regions for CNS therapies, nasal vaccines, and sensitive biologics.
• Soft Nasal Spray Adaptor A CE-marked single-use nasal administration device designed for liquids, used with a Luer-Lock syringe. Generates a tuneable soft mist with gentle low-shear spray principle for safe delivery of sensitive drugs, providing up to 50% coverage of the nasal cavity and optimal coverage of the olfactory region for nose-to-brain targeting.

Quantifiable outcome

• Over 60% lung deposition achieved with PFSI device
• +6 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Vectura: Specialist inhalation drug delivery company (now part of Philip Morris) developing dry powder and soft mist inhaler platforms for pharma partners. Direct comparable because Resyca's CTO and COO both held senior roles at Vectura, and Vectura targets the same pharma combination product licensing model across respiratory indications.
• Aptar Pharma: Major drug delivery device manufacturer offering nasal spray pumps, inhalation devices, and injectable systems to pharma partners. Comparable because Aptar competes for the same pharma combination product RFPs that Resyca targets, with overlapping nasal pump spray capabilities.
• Nemera: Drug delivery device company with a portfolio spanning nasal, ophthalmic, inhalation, and injectable delivery systems. Comparable because Nemera offers competing nasal spray and inhalation platforms to the same pharma customer base, with similar licensing-plus-supply commercial models.
• Stevanato Group: Pharmaceutical glass primary packaging and drug delivery systems manufacturer, including the Alba EZ-fill pre-filled syringe platform that Resyca integrates into PFSI. Comparable as both a strategic partner and a competing supplier of pre-fillable drug-device combination solutions for injectable and inhaled biologics.
• Gerresheimer: Pharmaceutical and biotech packaging specialist including glass syringes, pre-fillable systems, and inhalation device components. Comparable because Gerresheimer supplies primary packaging and drug-device combination components to the same pharma customer base that Resyca serves.

Broad incumbents

• Boehringer Ingelheim (Respimat): Owner of the Respimat soft mist inhaler, the established market-leading propellant-free inhaler used in marketed products such as Spiriva Respimat and Combivent Respimat. Direct comparable in soft mist inhalation technology and pharma combination products, but as a large incumbent pharmaceutical manufacturer rather than a specialist device licensor.
• West Pharmaceutical Services: Global leader in injectable drug delivery and containment including pre-filled syringe components, inhalation devices, and elastomeric seals. Comparable because West competes for pharma combination product device supply and is a natural strategic acquirer of specialised platforms like Resyca.
• Becton Dickinson (BD): Large diversified medical device and drug delivery company with significant presence in pre-filled syringes, injection systems, and respiratory drug delivery. Comparable as a broad incumbent competing for pharma device partnerships across nasal, pulmonary, and injectable delivery formats.
• Catalent: Major CDMO with drug delivery capabilities spanning inhalation, nasal, and injectable formats. Comparable as a partner-and-competitor for pharma combination product development services, particularly for soft mist and nasal biologic delivery programs.

Emerging players

• Hovione: CDMO with growing inhalation and nasal drug delivery capabilities including particle engineering and device formulation services. Comparable as a newer entrant in soft mist and nasal spray combination product development targeting similar pharma and biotech customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/resyca_smi
• LinkedInlinkedin.com/company/resyca

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resyca